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The triglycerides in chylomicrons are hydro-
lyzed by lipoprotein lipase (LpL) along the
luminal surface of the capillaries. However, the
endothelial cell molecule that facilitates chylo-
micron processing by LpL has not yet been
defined. Here, we show that glycosylphosphati-
dylinositol-anchored high-density lipoprotein-
binding protein 1 (GPIHBP1) plays a critical
role in the lipolytic processing of chylomicrons.
Gpihbp1-deficient mice exhibit a striking accu-
mulation of chylomicrons in the plasma, even
on a low-fat diet, resulting in milky plasma
and plasma triglyceride levels as high as
5000 mg/dl. Normally, Gpihbp1 is expressed
highly in heart and adipose tissue, the same tis-
sues that express high levels of LpL. In these
tissues, GPIHBP1 is located on the luminal
face of the capillary endothelium. Expression
of GPIHBP1 in cultured cells confers the ability
to bind both LpL and chylomicrons. These stud-
ies strongly suggest that GPIHBP1 is an impor-
tant platform for the LpL-mediated processing
of chylomicrons in capillaries.
INTRODUCTION
Dietary fats in mammals are packaged by the intestine
into chylomicrons, which are large triglyceride-rich lipo-
proteins (Havel and Kane, 2001). After reaching the
bloodstream, the triglycerides within chylomicrons areChydrolyzed by lipoprotein lipase (LpL) along the luminal
surface of capillaries, mainly in heart, skeletal muscle,
and adipose tissue (Havel and Kane, 2001; Nestel et al.,
1962). In those tissues, LpL is synthesized and secreted
by the parenchymal cells (i.e., myocytes and adipocytes)
and then translocated to the lumen of capillaries, where
lipolytic processing of chylomicrons occurs (Goldberg,
1996). The liver also secretes triglyceride-rich lipoproteins
called very low-density lipoproteins (VLDLs). The initial
phase of VLDL metabolism closely resembles that of chy-
lomicrons, with LpL-mediated hydrolysis of triglycerides in
the heart, skeletal muscle, and adipose tissue (Havel and
Kane, 2001; Nestel et al., 1962).
LpL is thought to bind to the surface of capillaries
through the interaction of its positively charged heparin-
binding domains (Sendak and Bensadoun, 1998) with
negatively charged heparan sulfate proteoglycans
(HSPGs) expressed on the surface of endothelial cells
(Goldberg, 1996; Parthasarathy et al., 1994). This concept
stems from the observation that LpL can be released from
the capillary endothelium with an injection of heparin
(Korn, 1955) and also from the fact that normal endothelial
cells bind more LpL than endothelial cells depleted of
HSPGs (Shimada et al., 1981). However, the precise en-
dothelial cell molecules required for the lipolytic process-
ing of chylomicrons have remained obscure (Goldberg,
1996).
A deficiency in LpL causes familial chylomicronemia,
which is characterized by extremely high levels of triglyc-
erides in the plasma (>2000 mg/dl) (Brunzell and Deeb,
2001). Familial chylomicronemia can also be caused by
a deficiency in apolipoprotein CII, a cofactor for LpL
(Bengtsson and Olivecrona, 1979; Breckenridge et al.,
1978). No cases of chylomicronemia have yet been as-
cribed to defects in endothelial cells affecting the binding
of either chylomicrons or LpL.ell Metabolism 5, 279–291, April 2007 ª2007 Elsevier Inc. 279
Cell Metabolism
GPIHBP1 in LipolysisFigure 1. Generation of Gpihbp1 Knockout Mice
(A) Sequence-replacement gene-targeting strategy for inactivating Gpihbp1. Locations of the 50 and 30 probes (bars) for Southern blot analysis and
PCR primers (arrows) for genotyping are shown. An ethidium bromide-stained agarose gel illustrates a PCR strategy for genotyping Gpihbp1+/+,
Gpihbp1+/, and Gpihbp1/ mice. A description of the PCR genotyping strategy is contained in the Experimental Procedures.
(B) A northern blot probed with a Gpihbp1 cDNA probe spanning the complete open reading frame of Gpihbp1 shows the absence of Gpihbp1 ex-
pression in heart and brown adipose tissue (BAT) from Gpihbp1/ mice.
(C) Western blot with GPIHBP1-specific rabbit antiserum showing GPIHBP1 in BAT and gonadal fat pad extracts from Gpihbp1+/+ mice, but not from
Gpihbp1/ mice. As a control, extracts from HeLa cells transfected with an untagged or S protein-tagged GPIHBP1 construct were included.In the current study, we examined the functional im-
portance of glycosylphosphatidylinositol-anchored high-
density lipoprotein-binding protein 1 (GPIHBP1) in plasma
lipid metabolism. GPIHBP1 was initially identified by ex-
pression cloning in Chinese hamster ovary (CHO) cells
as a glycosylphosphatidylinositol (GPI)-anchored cell-
surface protein that confers the ability to bind high-density
lipoproteins (Ioka et al., 2003). GPIHBP1 contains a highly
negatively charged amino-terminal domain (with 17 of 25
consecutive residues in the mouse sequence being gluta-
mate or aspartate) followed by a Ly-6 motif containing
multiple cysteines (Ioka et al., 2003).
Because GPIHBP1 was identified as an HDL-binding
protein, Ioka and coworkers (2003) speculated that it
might be involved in reverse cholesterol transport. Here,
we show that GPIHBP1 is a protein within the lumen of
capillaries that plays a critical role in the lipolytic process-
ing of triglyceride-rich lipoproteins.
RESULTS
Generation of Gpihbp1-Deficient Mice
To investigate the biological role of GPIHBP1 in plasma
lipid metabolism, we examined Gpihbp1-deficient mice
(Gpihbp1/ mice). Gpihbp1/ mice were produced by280 Cell Metabolism 5, 279–291, April 2007 ª2007 Elsevier Increplacing all of the exons and introns of Gpihbp1 with
lacZ and neo cassettes (Figure 1A). Southern blots show-
ing gene-targeting events are shown in Figure S1 in the
Supplemental Data available with this article online. North-
ern blots confirmed a complete absence of Gpihbp1 tran-
scripts in Gpihbp1/ mice (Figure 1B). By western blot,
GPIHBP1 could be detected in the adipose tissue of
wild-type mice but not Gpihbp1/ mice (Figure 1C).
Although the targeted Gpihbp1 allele contained a lacZ
reporter, lacZ transcripts were undetectable in knockout
mice (Figure S2), and no b-galactosidase activity could
be detected. The reason for the absence of lacZ ex-
pression in the Gpihbp1 knockout mice is not known
with certainty, but presumably it relates to the removal
of important regulatory elements contained within the
gene’s introns.
Gpihbp1-Deficient Mice Manifest Severe
Chylomicronemia
Both male and female Gpihbp1/ mice had milky plasma
on a normal chow diet (Figure 2A). This phenotype ap-
peared as early as 4 to 5 weeks of age and was invariably
present by 14 weeks of age. Plasma triglyceride levels
were significantly increased at all ages, with nearly all
mice having plasma triglyceride levels over 1000 mg/dl.
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GPIHBP1 in Lipolysisby 7–10 weeks of age, and some having triglyceride levels
as high as 5000 mg/dl (Figure 2B). Prior to weaning, the
plasma triglyceride levels in Gpihbp1/ pups were
slightly but significantly elevated compared with wild-
type mice (120 ± 12 versus 23 ± 16 mg/dl; p = 0.0023).
Plasma triglyceride levels in Gpihbp1+/ mice were indis-
tinguishable from those in Gpihbp1+/+ mice (Figure 2B).
Plasma cholesterol levels were also elevated in
Gpihbp1/ mice (Figure S3A).
The plasma lipoproteins of adult Gpihbp1/ mice
contained increased amounts of apo-B48 as judged by
a Coomassie blue-stained SDS-polyacrylamide gel (Fig-
ure 2C) and a western blot with a mouse apo-B-specific
monoclonal antibody (Nguyen et al., 2006) (Figure 2D).
Fractionation of the lipoproteins by fast protein liquid
chromatography (FPLC) revealed that the vast majority
of the triglycerides in the plasma of Gpihbp1/ mice
was in large lipoproteins (i.e., in the ‘‘chylomicron/VLDL’’
peak; Figure 2E). Most of the cholesterol in the plasma
was also located in the chylomicron/VLDL peak (Fig-
ure S3B). HDL cholesterol levels in Gpihbp1/ mice
were low (Figure S3B), as is generally the case with hyper-
triglyceridemia (Brunzell and Deeb, 2001). The diameters
of the triglyceride-rich lipoproteins in the plasma of
Gpihbp1/ mice were much larger than in wild-type
mice as judged by laser light scattering (Figure 2F) and
electron microscopy (Figure 2G).
The milky plasma in Gpihbp1/ mice, the increased
plasma levels of apo-B48, and the large lipoproteins sug-
gested a defect in the lipolytic processing of chylomi-
crons. To determine whether the processing of chylomi-
crons was abnormal, a retinyl palmitate clearance study
was performed. Following the oral administration of retinyl
palmitate, retinyl esters are packaged into chylomicrons in
the intestine and enter the circulation; the disappearance
of these retinyl esters from the plasma indicates the rate of
chylomicron clearance. In wild-type mice, plasma retinyl
ester levels peaked after 1–3 hr and had largely dis-
appeared by 10 hr (see inset in Figure 2H). In the
Gpihbp1/ mice, the peak retinyl ester levels were
more than 10-fold higher than those in Gpihbp1+/+ mice,
and very high levels persisted for 24 hr (Figure 2H).
GPIHBP1 Is Expressed on the Luminal Surface
of Capillary Endothelial Cells in Lipolytic Tissues
The finding of chylomicronemia in mice lacking a GPI-
anchored protein led us to hypothesize that GPIHBP1
might be involved in the processing of triglyceride-rich
lipoproteins by LpL at the surface of capillary endothelial
cells. In support of this idea, the tissue pattern of GPIHBP1
expression closely resembled that of LpL and CD36 (a pu-
tative fatty-acid transporter; Greenwalt et al., 1995). By
northern blot analysis, all three genes were expressed at
particularly high levels in adipose tissue and heart
(Figure S4). In addition, immunofluorescence microscopy
revealed that GPIHBP1 is expressed exclusively in endo-
thelial cells, colocalizing with the endothelial cell marker
CD31 (Figure 3A). Confocal immunofluorescence micros-
copy showed that GPIHBP1 was located on the luminalCface of capillaries in both brown adipose tissue and heart
(Figures 3B and 3C). GPIHBP1 was also expressed on the
capillaries of skeletal muscle, but in multiple experiments
was undetectable on the capillaries of the brain (Figure S5),
a tissue that relies heavily on glucose uptake rather than
on lipolysis of triglyceride-rich lipoproteins.
Postheparin Lipoprotein Lipase Activity Is Reduced
in Gpihbp1-Deficient Mice
We considered the hypothesis that GPIHBP1 might be the
sole binding site for LpL in capillaries and that the amount
of LpL bound to capillaries might be dramatically reduced
in Gpihbp1/ mice. To examine this possibility, we mea-
sured the levels of LpL and hepatic lipase (HL) in the
plasma after an injection of heparin (which releases LpL
from capillaries into the circulation). To avoid methodolog-
ical problems associated with measuring lipase activity in
lipemic serum, we separated LpL and HL in postheparin
plasma by heparin-Sepharose chromatography and then
quantified the HL and LpL activities (Figure 4). In four inde-
pendent experiments with age- and sex-matched plasma
samples, LpL activity was reduced by 53.3%, 27.2%,
16.6%, and 68.4% in Gpihbp1/ mice when compared
to wild-type mice, and the LpL:HL ratio in the Gpihbp1/
mice was reduced by 71.3%, 36.1%, 56.6%, and 90.4%
(p = 0.03). The HL activity tended to be higher in the
Gpihbp1/ mice, but these changes did not achieve sta-
tistical significance (p > 0.05).
We also measured LpL levels in whole plasma (i.e., not
fractionated on a heparin-Sepharose column) following an
injection of heparin. The postheparin LpL protein mass
levels were lower in Gpihbp1 knockout mice than in con-
trol mice (175 ± 111 ng/ml versus 581 ± 98 ng/ml; n = 5
for each group; p = 0.00028). Levels of LpL mass in the
preheparin plasma of wild-type and Gpihbp1/ mice
were very low and not different.
The fact that there was still some heparin-releasable
LpL in Gpihbp1/ mice suggested that other proteins,
perhaps HSPGs, provide a reservoir for LpL binding. Nev-
ertheless, the presence of GPIHBP1 within capillaries,
along with the chylomicronemia in Gpihbp1/ mice,
strongly suggested that GPIHBP1 is likely an important
platform for lipolysis. We hypothesized that GPIHBP1
might be capable of binding LpL, chylomicrons, or both.
This hypothesis seemed plausible given that GPIHBP1
contains a strongly negatively charged domain and that
both LpL and several apolipoproteins within chylomicrons
contain positively charged domains that are known to me-
diate protein-protein interactions (Brown and Goldstein,
1986; Cardin et al., 1989).
GPIHBP1 Binds Both Lipoprotein Lipase
and Chylomicrons
To test the hypothesis that GPIHBP1 binds to LpL and/or
chylomicrons, we constructed a full-length mouse
Gpihbp1 cDNA expression vector. Transient transfection
of CHO ldlA7 cells with a Gpihbp1 expression vector
yielded high levels of GPIHBP1 expression at the surface
of cells as judged by confocal fluorescence microscopyell Metabolism 5, 279–291, April 2007 ª2007 Elsevier Inc. 281
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GPIHBP1 in LipolysisFigure 2. Analysis of Gpihbp1 Knockout Mice
(A) Photograph of blood samples from three 2-month-old littermate chow-fed male mice (after low-speed centrifugation to sediment blood cells),
revealing milky plasma in Gpihbp1/ mice.
(B) Plasma triglyceride levels in Gpihbp1+/+, Gpihbp1+/, and Gpihbp1/ mice at different ages, showing higher triglyceride levels in Gpihbp1/
mice (p < 0.0001 in each age group). Triglyceride levels in Gpihbp1+/+ and Gpihbp1+/ mice were not different.
(C) Coomassie blue-stained SDS-polyacrylamide gel of the d < 1.006 g/ml lipoproteins of wild-type and Gpihbp1/ mice.
(D) Western blot of mouse plasma (1.0 ml) with mouse monoclonal antibody specific for apo-B48 and apo-B100 (Nguyen et al., 2006), showing
increased amounts of apo-B48 in the plasma of Gpihbp1/ mice.
(E) Distribution of triglycerides in the plasma lipoproteins ofGpihbp1+/+ andGpihbp1/ mice. Plasma lipoproteins were separated by size on a Super-
ose 6 FPLC column. Data are representative of two different experiments.
(F) Distribution of lipoprotein sizes in the d < 1.022 g/ml lipoproteins from Gpihbp1/ and Gpihbp1+/+ mice as judged by dynamic laser light scat-
tering. The median diameter of lipoproteins inGpihbp1/ mice (n = 3) was 157% larger than inGpihbp1+/+ mice (n = 6). Shown here are representative
data from a single Gpihbp1/ and Gpihbp1+/+ mouse. Both Gpihbp1+/+ and Gpihbp1/ mice had bimodal distributions of lipoproteins: the larger
subpopulation of particles in Gpihbp1/ mice, constituting 15.4% of the total particles, had diameters of 122–289 nm; the larger subpopulation
of particles in Gpihbp1+/+ mice, constituting 2.9% of the total particles, had diameters of 94–204 nm. The smaller subpopulation of particles in
Gpihbp1/ and Gpihbp1+/+ mice had diameters of 39–111 and 33–86 nm, respectively.
(G) Electron micrographs of negatively stained d < 1.006 g/ml lipoproteins from the plasma of Gpihbp1/ and Gpihbp1+/+ mice, showing the larger
lipoproteins in Gpihbp1/ mice. Representative images from two Gpihbp1/ and two Gpihbp1+/+ samples are shown.282 Cell Metabolism 5, 279–291, April 2007 ª2007 Elsevier Inc.
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GPIHBP1 in Lipolysis(Figure 5A). This GPIHBP1 could be released from the sur-
face of cells with a phosphatidylinositol-specific phospho-
lipase C (PIPLC) (Low, 1992) (Figure 5B). To assess the
ability of GPIHBP1 to bind LpL, we examined the binding
of LpL to a mutant CHO cell line (pgsA-745) that lacks the
ability to synthesize HSPGs (Lugemwa and Esko, 1991).
(H) Delayed clearance of retinyl esters in Gpihbp1/ mice. Retinyl palmitate (5000 IU in 50 ml of vegetable oil) was administered to mice by gavage,
and retinyl esters in the plasma were measured over the next 24 hr. The inset shows retinyl ester levels in Gpihbp1+/+ mice plotted on a smaller scale,
showing that the levels inGpihbp1+/+ mice peaked between 1 and 3 hr and largely disappeared by 10 hr. Retinyl palmitate clearance studies were also
performed in Gpihbp1+/ mice, with results indistinguishable from those of Gpihbp1+/+ mice. The retinyl palmitate clearance studies were performed
in seven Gpihbp1/, six Gpihbp1+/, and five Gpihbp1+/+ mice. Shown here are representative curves for three Gpihbp1/ and Gpihbp1+/+ mice.
When the retinyl ester measurements for all of the mice were analyzed, the differences between the Gpihbp1/ mice and the other two groups were
statistically significant at each time point (p < 0.001). There were no differences between Gpihbp1+/ and Gpihbp1+/+ mice.
Figure 3. GPIHBP1 Is Located within the Lumen of the Capillary Endothelium of Brown Adipose Tissue and Heart
(A) Epifluorescence microscopy showing the binding of rat monoclonal antibody against mouse CD31 (red) and rabbit antiserum against GPIHBP1
(green) to brown adipose tissue of Gpihbp1+/+ and Gpihbp1/ mice. Images were taken with a 403 objective.
(B) Confocal microscopy images showing the binding of antibodies against CD31 and GPIHBP1 to brown adipose tissue from a Gpihbp1+/+ mouse.
Images were taken with a 1003 objective. The arrow indicates the location of a capillary (shown at higher magnification in the insert; 1003 objective
with 43 digital zoom). The high-magnification micrograph shows a cross-section of a capillary, revealing that GPIHBP1 staining is particularly prom-
inent on the luminal side of the capillary.
(C) Confocal microscopy images showing the binding of antibodies against CD31 and GPIHBP1 to heart tissue from a Gpihbp1+/+ mouse. GPIHBP1
staining is particularly prominent on the luminal face of the capillary endothelium. Images were taken with a 1003 objective.Cell Metabolism 5, 279–291, April 2007 ª2007 Elsevier Inc. 283
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GPIHBP1 in LipolysisCHO pgsA-745 cells stably transfected with Gpihbp1
bound 10- to 20-fold more LpL than cells transfected
with empty vector, and the binding of LpL to cells was
saturable, with nonspecific binding being negligible
(Figure 5C). An analysis of LpL binding indicated that
GPIHBP1 binds LpL tightly (calculated Kd = 3.63 10
8 M).
The increased binding of LpL toGpihbp1-transfected cells
Figure 4. Separation of LpL andHL in the Postheparin Plasma
of Gpihbp1/ and Wild-Type Mice on a Heparin-Sepharose
Column
(A) Lipase activity in the different fractions (data are representative of
four independent experiments).
(B and C) In these studies, the identities of the LpL (B) and HL (C) peaks
were verified with immunoassays (Cisar et al., 1989). The specific ac-
tivity of the LpL in fractions 21–25 of the wild-type and Gpihbp1/
mouse plasma was not different. Each data point represents the aver-
age of duplicate analyses.284 Cell Metabolism 5, 279–291, April 2007 ª2007 Elsevier Inc.was eliminated by treating the cells with PIPLC
(Figure 5D). Heparin was effective in releasing LpL from
GPIHBP1 expressed on the surface of pgsA-745 cells
(Figures 5E and 5F).
To determine whether GPIHBP1 binds to triglyceride-rich
lipoproteins, we isolated the d < 1.006 g/ml lipoproteins
(‘‘chylomicrons’’) from the plasma of Gpihbp1/ mice, la-
beled them with the fluorescent dye 1,10-dioctadecyl-
3,3,30,30-tetramethylindocarbocyanine perchlorate (DiI),
and incubated them with CHO ldlA7 cells stably trans-
fected with the mouse Gpihbp1 cDNA or empty vector.
The Gpihbp1-transfected cells bound chylomicrons av-
idly, whereas the cells transfected with the empty vector
did not (Figure 6A). The binding of chylomicrons was dra-
matically reduced by treating the transfected cells with
PIPLC (Figure 6A). In transient transfection experiments,
10% of the cells expressed GPIHBP1 as judged by
immunofluorescence microscopy, and only those cells
bound chylomicrons (Figure 6B). In similar experiments,
we found that Gpihbp1-transfected cells also bound
apo-AV-phospholipid disks (Figure S6).
Gpihbp1 Expression Levels in Muscle Change
with Feeding Status
Lipolysis of triglyceride-rich lipoproteins is controlled at
multiple steps, according to metabolic need. For example,
LpL activity levels in muscle are controlled by feeding
status (Lithell et al., 1978). We therefore tested whether
Gpihbp1 expression in muscle changes with feeding
status. Indeed, Gpihbp1 expression increased 2-fold in
muscle during fasting (p < 0.001) (Figure 7).
DISCUSSION
In this study, we show that adult Gpihbp1/ mice have
severe hypertriglyceridemia associated with a marked de-
lay in the clearance of retinyl palmitate from the plasma.
Gpihbp1 is expressed at high levels in heart, adipose tis-
sue, and skeletal muscle—the same tissues that express
high levels of LpL. In these tissues, GPIHBP1 is located
on the luminal face of the capillary endothelium. Expres-
sion of GPIHBP1 in cultured cells confers the ability to
bind both LpL and chylomicrons. Together, these findings
strongly suggest that GPIHBP1 is a key platform for the
LpL-mediated processing of chylomicrons in capillaries.
We found a large difference in GPIHBP1 expression in
different capillary beds. While GPIHBP1 was expressed
highly on the capillaries of lipolytic tissues such as adipose
tissue, heart, and skeletal muscle, it was virtually absent in
the brain. These findings raise the possibility that differ-
ences in endothelial cell gene expression could play an
active role in regulating the delivery of lipid nutrients to
different tissues.
The ability of GPIHBP1 to bind both to LpL and chylomi-
crons favors the concept that GPIHBP1 serves as an im-
portant platform for lipolysis by drawing chylomicrons
and LpL into close proximity. However, it is unlikely that
Gpihbp1 deficiency completely eliminates LpL-mediated
processing of lipoproteins. Lpl-deficient mice die shortly
Cell Metabolism
GPIHBP1 in LipolysisFigure 5. Generating Cell Lines Expressing a Gpihbp1 cDNA and Testing the Ability of GPIHBP1 to Bind LpL
In preliminary studies, we showed that the expression of Gpihbp1 was absent in wild-type CHO cells.
(A) Confocal immunofluorescence microscopy showing the expression of an S protein-tagged GPIHBP1 on the surface of CHO ldlA7 cells. GPIHBP1
was visualized with a FITC-conjugated goat antibody against the S protein tag (green), and DNA was visualized with DAPI (blue).
(B) Western blot analysis of cell extracts and cell culture medium from HeLa cells transfected with a mouseGpihbp1 cDNA, before and after treatment
of the cells with PIPLC.
(C) Binding of LpL to pgsA-745 CHO cells stably transfected with a cDNA encoding mouse Gpihbp1 (pcDNA3-Gpihbp1; see Experimental Proce-
dures) or empty vector. Cells were incubated for 2 hr with increasing amounts of avian LpL. Following the incubation, the amount of bound LpL
was measured by ELISA. Each data point represents the mean of triplicates ± SD; the standard deviations are too small to be seen.
(D) Binding of avian LpL (2.5 mg/ml) to pgsA-745 CHO cells transfected with pcDNA3-Gpihbp1 or empty vector, before and after treatment with PIPLC.
Each bar represents the mean of triplicates ± SD; in some cases, the standard deviations are too small to be seen. In parallel experiments, pgsB-761
CHO cells transfected with the Gpihbp1 cDNA also bound 10-fold more LpL than cells transfected with the empty vector. In wild-type CHO cells, LpL
binding to nontransfected cells was greater (as a result of the expected binding of LpL to HSPGs), but we consistently observed a 70% increase in LpL
binding to Gpihbp1-transfected cells.
(E) Binding of avian LpL (2.5 mg/ml) to pgsA-745 CHO cells transfected with pcDNA3-Gpihbp1 or empty vector, before and after treatment with
heparin (1 U/ml).
(F) Western blot analysis of cell extracts and cell culture medium from pgsA-745 CHO cells transfected with a mouse Gpihbp1 cDNA (tagged and
untagged) or empty vector, alone or in combination with a human LPL cDNA (with a C-terminal V5 tag), before and after treatment of the cells
with heparin (1 U/ml).Cell Metabolism 5, 279–291, April 2007 ª2007 Elsevier Inc. 285
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GPIHBP1 in LipolysisFigure 6. Binding of Chylomicrons to CHO-ldlA7 Cells Expressing Mouse GPIHBP1
(A) The binding of DiI-labeled chylomicrons (red) to nonpermeabilized CHO-ldlA7 cells stably transfected with a mouse Gpihbp1 cDNA (or empty
vector) was measured at 4C, before and after PIPLC treatment. GPIHBP1 expression was detected with rabbit anti-GPIHBP1 antiserum and
a FITC-labeled anti-rabbit IgG antibody (green), and DNA was visualized with DAPI (blue).
(B) Binding of DiI-labeled chylomicrons (red) to CHO-ldlA7 cells transiently transfected with a mouse Gpihbp1 cDNA. GPIHBP1 expression was
detected as described in (A).after birth, with plasma triglyceride levels as high as
20,000 mg/dl (Weinstock et al., 1995), whereas
Gpihbp1/ mice survive and have far lower triglyceride
levels. These differences between Gpihbp1- and Lpl-defi-
cient mice strongly suggest that some LpL-mediated lipol-
ysis occurs in the absence of GPIHBP1. Without question,
LpL is present in Gpihbp1/ mice; we clearly identified
mouse LpL—with normal enzymatic activity—in the
plasma of Gpihbp1/ mice after an injection of heparin.
The fact that LpL was identified in the postheparin
plasma of Gpihbp1/ mice indicates that, in vivo, there
are additional binding sites for LpL aside from GPIHBP1.
Cell culture experiments have shown, quite convincingly,
that LpL binds to HSPGs on the surface of endothelial
cells (Cheng et al., 1981). However, at this point, we do286 Cell Metabolism 5, 279–291, April 2007 ª2007 Elsevier Inc.not know with certainty whether the heparin-releasable
LpL in Gpihbp1/ mice is attached to HSPGs or whether
the LpL in Gpihbp1/ mice that is mobilized by heparin is
actually located within the lumen of capillaries. At this
time, it is also not known with certainty how much of the
LpL found in the bloodstream after an injection of heparin
is actually released from the luminal surface of capillaries
versus other sites (e.g., parenchymal cells, basement
membranes, and subendothelial spaces). Furthermore,
the percentage of postheparin LpL that arises from endo-
thelial cells versus those other sites could differ in
Gpihbp1/ and Gpihbp1+/+ mice. In any case, since the
postheparin plasma LpL levels are higher in wild-type
mice than inGpihbp1/mice, it seems possible that a sig-
nificant fraction of the heparin-releasable LpL in wild-type
Cell Metabolism
GPIHBP1 in Lipolysismice is bound by GPIHBP1. In future studies, it will be of
interest to determine the fraction of the total LpL pool on
endothelial cells that is bound to GPIHBP1 and HSPGs
and whether LpL bound to GPIHBP1 is catalytically
more efficient than LpL bound to HSPGs.
The degree of hypertriglyceridemia in Gpihbp1/ pups
before weaning was milder than that in 4- to 6-week-old
Gpihbp1/ mice, which in turn was milder than that in
7- to 16-week-old Gpihbp1/ mice. The explanation for
this finding is not known with certainty, but we suspect
that it relates to the fact that Lpl mRNA levels are much
higher in the liver during the suckling phase (Langner
et al., 1989). We have confirmed higher Lpl expression
levels by quantitative RT-PCR: suckling C57BL/6 mice
have hepatic Lpl mRNA levels 50 times greater than those
of 10-week-old mice, and hepatic Lpl mRNA levels in
4-week-old mice are approximately double those in
10-week-old mice (Figure S7). Although we have not yet
proven that the differences in hepatic expression of Lpl
are responsible for the lower triglyceride levels in the
younger mice, the time course of Lpl expression would
be consistent with this possibility. In any case, we empha-
size that the defect in LpL activity in adult Gpihbp1/
mice is severe. When newborn Lpl knockout mice were in-
jected with an LpL adenovirus, some survived the suckling
period, owing to the adenovirus-mediated LpL expression
in the liver (Strauss et al., 2001). However, this adenovirus-
mediated LpL expression disappeared by 30 days of age.
After the extinction of LpL expression, the plasma
triglyceride levels in the rescued mice were 2000–5000
mg/dl—very similar to those in chow-fed Gpihbp1/
mice in this study.
The plasma levels of apo-B48 were markedly elevated
inGpihbp1/ mice. In the mouse, apo-B48 is synthesized
by both the liver and the intestine (Hirano et al., 1996).
Given the markedly delayed clearance of retinyl palmitate
inGpihbp1/ mice, we suspect that much of the apo-B48
accumulation is due to delayed clearance of intestinal li-
Figure 7. Regulation of Gpihbp1 Expression in Quadriceps
According to Feeding Status
RNA was isolated from fed mice, fasted mice (16 hr), and fasted/refed
mice (6 hr post refeeding a high-carbohydrate diet) (10-week-old wild-
type C57BL/6 male mice; n = 10 per group), and the expression of
Gpihbp1 was measured by quantitative RT-PCR (mean ± SD). Data
were normalized to b2-microglobulin expression. Values show the
amount of Gpihbp1 mRNA relative to that in fed mice. ***p < 0.001.Cpoproteins. However, the lipolytic processing of chylomi-
crons and hepatic VLDL are similar, and there is no reason
to believe that the accumulation of apo-B48 is exclusively
due to an accumulation of intestinal lipoproteins.
The molecular basis for chylomicron binding to
GPIHBP1 requires further study. Chylomicrons contain
several apolipoproteins (e.g., apo-B48, apo-E, and
apo-AV) that have positively charged domains that bind
to heparin sulfate and/or HSPGs (Cardin et al., 1984,
1986; Lookene et al., 2005), so it is easy to imagine that
one or more of these apolipoproteins could mediate the
binding of chylomicrons to the strongly negatively
charged domain of GPIHBP1. In particular, apo-AV would
make a good candidate as a ligand for GPIHBP1, given
that Apoav deficiency causes hypertriglyceridemia asso-
ciated with decreased LpL-mediated lipolysis (Calandra
et al., 2006; Grosskopf et al., 2005; Pennacchio et al.,
2001). In support of this idea, our studies showed that
apo-AV-phospholipid disks bind avidly to Gpihbp1-trans-
fected proteoglycan-deficient cells (Figure S6). Another
interesting hypothesis is that GPIHBP1 could act as a
receptor for apo-B48, a key structural protein of large tri-
glyceride-rich lipoproteins. It would make sense if a recep-
tor for apo-B48 were located in the capillary endothelium
of muscle and fat, where lipolysis occurs. Also, this hy-
pothesis is in line with evolutionary considerations. Both
apo-B48 and chylomicrons (defined as intestinal lipopro-
teins that are secreted into the lymph) are unique to mam-
mals (Teng and Davidson, 1992). Similarly, GPIHBP1—
defined as a GPI-anchored Ly-6-motif protein with a
very strong acidic domain—is present in all mammals
but is absent in fish, amphibians, and birds.
Transfection of a Gpihbp1 cDNA into cultured cells pro-
motes the binding of both LpL and chylomicrons, but it is
not yet clear whether a single GPIHBP1 molecule is capa-
ble of binding chylomicrons and LpL simultaneously. If
a single GPIHBP1 molecule binds only a single ligand,
chylomicrons and LpL could still be drawn together if the
GPIHBP1 molecules were clustered together on the cell
surface. This possibility seems plausible given that other
GPI-anchored proteins are concentrated within lipid rafts
on the plasma membrane (Varma and Mayor, 1998).
Also, GPIHBP1 could exist as a homodimer on the cell sur-
face and therefore bind to more than one ligand. Of note,
urokinase-type plasminogen activator receptor, a related
GPI-anchored Ly-6-motif protein, exists as a dimer on
the cell surface (Cunningham et al., 2003).
In summary, GPIHBP1 is crucial for the lipolytic pro-
cessing of triglyceride-rich lipoproteins. It is located on
the luminal surface of the capillary endothelium and binds
both LpL and chylomicrons. It likely forms a platform for li-
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GPIHBP1 in Lipolysisa lacZ reporter and a PGK-neo cassette. Targeted cells were identified
by Southern blotting of genomic DNA with 50- and 30-flanking probes.
The 50 probe was amplified from genomic DNA with oligonucleotides
50-GGTCTGTAGCAAGCCTTCC-30 and 50-GTGTCCTTCCTGCCAAAT
CC-30 (after cleaving genomic DNA with HpaI, the targeted band is
11.8 kb, and the wild-type band is 17.1 kb). The 30 probe was amplified
with oligonucleotides 50-CATCTGTACAGCCCTTGTCC-30 and 50-CCA
GAAGCACAACAGCCAG-30 (after cleaving genomic DNA with EcoRI,
the targeted band is 7.1 kb, and the wild-type band is 8.5 kb). Routine
genotyping was performed by PCR; the mutant allele was detected by
PCR with oligonucleotides 50-GCAGCGCATCGCCTTCTATC-30 and
50-GGAGGCCTACACTAGAAGG-30 (amplifying a 655 bp PCR product
between the neo cassette and sequences 30 to Gpihbp1). The wild-
type allele was detected by PCR with oligonucleotides 50-GGTGA
TGCGGACCCGGAG-30 and 50-GTGTCTGATTGCAGCTCTCC-30 (am-
plifying a 519 bp PCR product spanning intron 2). All mice had a mixed
genetic background (<10% 129/Sv and >90% C57BL/6). The mice
were fed a chow diet and housed in a virus-free barrier facility with
a 12 hr light/dark cycle. All studies were approved by UCLA’s Commit-
tee on Animal Research.
Northern Blots
Total RNA was prepared from mouse tissues with TRI Reagent
(Sigma), size fractionated on a 1% agarose/formaldehyde gel, and
transferred to a sheet of Nytran SuPerCharge membrane (Schleicher
and Schuell). The blot was hybridized to 32P-labeled cDNAs for mouse
Gpihbp1, human LPL, mouse Cd36, and mouse 18S ribosomal RNA.
Quantitative RT-PCR
Total RNA was prepared from mouse tissues with TRI Reagent
(Sigma), treated with DNase I (Ambion), and reversed transcribed
into cDNA with a mixture of random primers and oligo(dT) and Super-
script III (Invitrogen). Primers for each gene were designed with the
Primer 3 program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_
www.cgi) and assessed by DART-PCR (Peirson et al., 2003) to validate
equivalent efficiencies between genes and the endogenous control
gene (b2-microglobulin). Quantitative PCR analysis was performed
on 50 ng cDNA, 200 nM of each primer, and 10 ml of SYBR Green
PCR Master Mix (QIAGEN). PCR reactions were performed in triplicate
on a 7500 Fast Real-Time PCR System from Applied Biosystems. The
relative expression of all gene-specific mRNA was calculated by the
comparative CT method.
Rabbit Antiserum against Mouse GPIHBP1
A segment of the mouse Gpihbp1 cDNA (spanning nucleotides 88–
636, corresponding to amino acids 23–205) (NM_026730) was cloned
into the BamHI and SalI sites of pQE-30 (QIAGEN) to create a bacterial
expression vector for His6-tagged GPIHBP1. This fragment was ampli-
fied from mouse adipose tissue cDNA with forward primer 50-CC
ATCACGGATCCGCACAAGAAGATGGTGATGCGGA-30 and reverse
primer 50-GCTGCAGGTCGACGCCTGAAGGGTATCCTGCCCCAC-30
(underlined sequences indicate restriction endonuclease sites). The
plasmid was transformed into E. coli Max 5aF0 cells. Bacteria from
1.0 l cultures were resuspended with 40 ml of lysis buffer (20 mM
Na2HPO4 [pH 7.0], 250 mM NaCl, 6 M guanidinium chloride) and lysed
by 15 successive 10 min periods of sonication (at a power of 50 W) al-
ternating with 10 min incubations on ice. The lysate was stirred at room
temperature for 30 min and then centrifuged at 4000 3 g for 30 min in
an SS34 rotor. The supernatant fluid was then incubated with 2 ml of
TALON metal affinity resin (Clontech) with continuous stirring for
60 min at 4C. The resin was sedimented by low-speed centrifugation,
loaded onto a column, and washed overnight with 1 l of wash buffer
containing 20 mM Na2HPO4 (pH 7.0), 250 mM NaCl, 8 M urea, and
5 mM imidazole. The recombinant GPIHBP1 fragment was eluted
with a 30 ml linear gradient of imidazole (5–300 mM) in wash buffer.
Three milliliter fractions were collected, and aliquots were size fraction-
ated on SDS-polyacrylamide gels. Fractions containing the His6-
GPIHBP1 fragment (identified by Coomassie blue staining) were288 Cell Metabolism 5, 279–291, April 2007 ª2007 Elsevier Inc.pooled and dialyzed against PBS containing 0.02% sodium azide.
Two rabbits were immunized with the GPIHBP1 fragment (75 mg/
rabbit) in complete Freund’s adjuvant and then boosted with the
GPIHBP1 fragment (150 mg/rabbit) in incomplete Freund’s adjuvant 3
and 6 weeks later.
Analysis of the Plasma Lipoproteins
Plasma cholesterol and triglyceride levels were measured on non-
fasted plasma samples with the Serum Triglyceride Determination
Kit (Sigma) and Cholesterol E kit (Wako). Fractionation of mouse
plasma lipoproteins was performed by FPLC (Cole et al., 1988). The di-
ameters of lipoprotein particles in the d < 1.022 g/ml fraction of plasma
were measured with a Nanotrac 250 particle analyzer (Microtrac) fitted
with a flexible conduit-sheathed probe (Walzem et al., 1994). Lipopro-
tein particle diameters were recorded as frequency distributions of
particles within a given diameter interval. Negatively stained lipopro-
teins (d < 1.006 g/ml fraction) from the plasma of Gpihbp1/ and
Gpihbp1+/+ mice were imaged by electron microscopy (Hamilton
et al., 1980). The protein composition of lipoproteins was analyzed
by SDS-PAGE followed by Coomassie blue staining.
Western Blots
Proteins from tissue or cell culture extracts (20 mg) were size fraction-
ated on 4%–12% Bis-Tris gradient SDS-polyacrylamide gels and then
transferred to nitrocellulose membranes for western blots. The anti-
body dilutions were 1:500 for mouse monoclonal antibody against
mouse apo-B48 and apo-B100 (Nguyen et al., 2006), 1:500 for rabbit
antiserum against GPIHBP1, 1:500 for mouse antibody against V5
tag (Invitrogen), 1:500 for mouse monoclonal antibody against b-actin
(Abcam), 1:5000 for HRP-labeled anti-mouse IgG (NA931V, GE Health-
care), 1:5000 for HRP-labeled anti-rabbit IgG (NA934V, GE Health-
care), 1:2000 for IRDye680-conjugated goat anti-rabbit IgG (Li-Cor),
and 1:2000 for IRDye800-conjugated goat anti-mouse IgG (Li-Cor).
Antibody binding was detected with the ECL Plus chemiluminescence
system (GE Healthcare) and exposure to X-ray film. When the IRDye-
conjugated secondary antibodies were used, binding was detected
with an Odyssey infrared scanner (Li-Cor).
Measurement of Retinyl Esters
Mice were given 5000 IU of retinyl palmitate (all-trans) or vehicle alone
(soybean oil) by oral gavage (50 ml). Blood samples were taken
immediately after gavage and 1, 2, 4, 10, and 24 hr later. Plasma levels
of retinyl esters were measured by HPLC on a 2503 4.6 mm Beckman
Ultrasphere C18 column (Mills et al., 1992; Redlich et al., 1996). Retinyl
esters were separated in a mobile phase consisting of acetonitrile:
methanol:dichloromethane (70:15:15 v/v) at a flow rate of 1.8 ml/min
and detected by UV absorbance at 325 nm with a Waters 996 photo-
diode array detector. Retinyl acetate was used as an internal standard.
Retinyl ester standards were synthesized from authentic all-trans
retinol and the corresponding fatty acyl chloride (Blaner et al., 1994).
The reported plasma retinyl ester concentrations represent the sum
of individual retinyl ester concentrations (retinyl linoleate, retinyl oleate,
retinyl palmitate, and retinyl stearate). All extraction and HPLC proce-
dures were carried out under N2 and reduced light to prevent oxidation
of the compounds. Plasma samples (25–200 ml) were denatured with
an equal volume of absolute ethanol containing known amounts of
retinyl acetate and then extracted into hexane. Following phase sepa-
ration, the hexane extract was evaporated under a stream of N2, and
the residue was resuspended in benzene for injection onto the HPLC
column. The lower limit of detection for retinyl esters was 2 ng/ml
(Burger et al., 1997).
Expression of Mouse Gpihbp1 in CHO Cells
Two independent strategies were used to express a mouse Gpihbp1
cDNA in cultured cells. In strategy 1, the complete coding sequence
of Gpihbp1 (nucleotides 1–711) was amplified from a mouse adipose
cDNA library with the primers 50-CTCGAGCGGCCGCGACAGAA
CAGCCTGAGCCAGGAT-30 (underlined segment is a NotI site) and
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GPIHBP1 in Lipolysis50-TTAAGCTTGGTACCTCTTCAGGCCCCTGACGCCCAC-30 (under-
lined segment is a KpnI site). The fragment was ligated into the NotI
and KpnI sites of pcDNA3.1() (Invitrogen) to produce pcDNA3-
Gpihbp1. CHO-K1 cells, Ldlr-deficient CHO cells (ldlA7 cells, a gener-
ous gift from M. Krieger) (Kingsley and Krieger, 1984), and CHO cells
deficient in the ability to synthesize heparan sulfate proteoglycans
(pgsA-745 and pgsB-761 cells, a generous gift from J. Esko) (Esko,
1991) were transfected with pcDNA3-Gpihbp1 or empty vector using
FuGENE 6 Transfection Reagent (Roche) according to the manufac-
turer’s instructions. Stably transfected cells were obtained following
selection with G418 (0.5 mg/ml). The cells were then subjected to
a second round of transfection with pcDNA3-Gpihbp1 and pCMV/
Bsd (Invitrogen) and selected with blasticidin (5 mg/ml). In strategy 2,
an IMAGE clone (ID #30298145) containing the complete open reading
frame of mouse Gpihbp1 in pDNR-LIB was purchased from Open Bio-
systems. An NcoI restriction site immediately upstream of the transla-
tional start site was created by site-directed mutagenesis (Quik-
Change Site-Directed Mutagenesis Kit, Stratagene). An NcoI-HindIII
fragment containing the complete open reading frame was subcloned
into the mammalian expression vector pTriEx-4 (Novagen). To facili-
tate subsequent cloning steps, the ApaI site in pTriEx-4 was replaced
with an SfoI restriction site by site-directed mutagenesis. An ApaI site
was subsequently created by silent mutation at nucleotide 66 of the
Gpihbp1 cDNA (between the signal peptide and the acidic domain).
A Gpihbp1 construct with an amino-terminal S protein tag was created
by inserting the S protein coding sequence (50-AAAGAAACCGCTGCT
GCGAAATTTGAACGCCAGCACATGGACTCG-30) into the newly cre-
ated ApaI site. The integrity of all constructs was verified by DNA
sequencing.
Immunofluorescence Microscopy
For the detection of GPIHBP1 in cultured cells, cells were plated on
coverslips at25,000 cells per well in 24-well plates, fixed in 3% para-
formaldehyde, blocked with 10% sheep serum, and incubated with the
rabbit anti-GPIHBP1 antiserum diluted in blocking buffer (1:800). De-
tergents were omitted to facilitate the detection of only cell-surface
GPIHBP1 protein. Bound rabbit IgG was detected with a FITC-conju-
gated donkey anti-rabbit IgG (1:800, Jackson ImmunoResearch). After
washing, cells were stained with DAPI to visualize DNA. For cells trans-
fected with the S protein-tagged GPIHBP1 construct, the fusion pro-
tein was detected with a FITC-conjugated goat antibody against the
S protein tag (1:400, Abcam). Images were obtained with an Axiovert
200 MOT microscope (Zeiss) with a 633/1.25 oil-immersion objective
and processed with AxioVision 4.2 software (Zeiss). Confocal fluores-
cence microscopy was performed with a Leica TCS-SP MP confocal
inverted microscope equipped with an argon laser (488 nm blue exci-
tation), a diode laser (561 nm green excitation), and a two-photon laser
tuned at 768 nm for UV excitation. Individual images were captured se-
quentially with a 633/1.32 plan apo objective, and merged images
were generated with Leica Confocal Software (version 2.5).
For the detection of GPIHBP1 in mouse tissues, 10 mm frozen sec-
tions were fixed with 4% formaldehyde and blocked with 10% donkey
serum. The samples were incubated overnight with the rabbit antise-
rum against mouse GPIHBP1 (1:200) and rat monoclonal antibody
against mouse CD31 (1:50, BD Pharmigen). Samples were subse-
quently washed and incubated for 1 hr with FITC-conjugated antibody
against rabbit IgG (1:200, Jackson ImmunoResearch) and Alexa Fluor
568-conjugated antibody against rat IgG (1:800, Molecular Probes).
After washing, the sections were stained with DAPI to visualize DNA.
Microscopy was performed as described above.
Binding of Lipoprotein Lipase to Gpihbp1-Transfected
CHO Cells
CHO pgsA-745 cells transfected with pcDNA3-Gpihbp1 or empty vec-
tor were grown to confluence in Ham’s F12 medium containing 5%
fetal bovine serum. The cells were placed on ice, washed twice with
ice-cold PBS, and incubated for 2 hr at 4C with 1.0 ml of Ham’s
F12 medium supplemented with 0.5% BSA and highly purified chickenCLpL (Bensadoun et al., 1999). After this incubation, the cells were
washed once with PBS supplemented with 0.5% BSA and lysed with
400 ml of CHAPS lysis buffer (4 mM CHAPS, 50 mM NH4Cl, and 3 U
heparin/ml). The amount of LpL in the medium and cell lysates was
measured by ELISA (Cisar et al., 1989).
Experiments were also performed to determine whether the binding
of LpL to cells could be prevented by treating cells with a phosphatidyl-
inositol-specific phospholipase C (PIPLC). CHO-pgsA-745 cells trans-
fected with either pcDNA3-Gpihbp1 or empty vector were grown to
confluence in 35 mm dishes. The cells were incubated in 2 ml of
Ham’s F12 in the absence or presence of 10 U of PIPLC at 37C for
1 hr. Cells were then placed on ice and incubated in Ham’s F12 supple-
mented with 0.5% BSA and 1.5 mg of avian LpL for 2 hr. Cells were then
washed once with PBS/0.5% BSA and lysed with CHAPS buffer.
Bound LpL was determined by ELISA (Cisar et al., 1989). Recombinant
PIPLC was purified from the media of Bacillus subtilis transfected with
a PIPLC gene from B. thuringiensis (a generous gift from M. Low) (Low,
1992). The enzyme was purified from media by ion-exchange chroma-
tography on Amberlite CG-50, followed by ammonium sulfate precip-
itation, gel filtration on Sephadex G-75, and a final anion-exchange
chromatography step on MonoQ. PIPLC activity was documented
with L-3-phosphatidyl[2-3H]inositol (GE Healthcare) (Low, 1992). The
final PIPLC preparation had an activity of 199 units/ml.
Measurements of LpL and Hepatic Lipase Activities
To estimate LpL and HL activities in postheparin plasma, mice were in-
jected intraperitoneally with 0.5 U heparin sodium/g body weight, and
blood was collected under anesthesia from the retro-orbital sinus
15 min later. To avoid the possibility of the elevated plasma triglyceride
levels interfering with the lipase assays, the lipases were partially puri-
fied from the plasma samples by heparin-Sepharose chromatography.
Postheparin plasma (200 ml) was loaded onto 1.0 ml heparin-Sephar-
ose HiTrap columns (GE Healthcare) equilibrated with 0.25 M NaCl,
20% glycerol, 1% BSA, 10 mM sodium phosphate (pH 6.5). The col-
umns were washed with 10 ml of the equilibration buffer and eluted
with a 30 ml NaCl gradient (0.25–1.5 M in 20% glycerol, 1% BSA,
10 mM sodium phosphate [pH 6.5]). Fractions were assayed for lipo-
lytic activity with [3H]triolein as described previously (Hocquette
et al., 1998). The activities in fractions corresponding to the HL and
LpL peaks were added together to calculate the lipase activities per
ml of plasma.
Binding of DiI-Labeled Chylomicrons to Cells
DiI (1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine perchlo-
rate) was purchased from Invitrogen. DiI was dissolved in DMSO
(3 mg/ml), and 10 ml of this solution was added to 70 ml of serum
from a Gpihbp1/ mouse and 250 ml of human lipoprotein-deficient
serum. This mixture was then incubated at 37C overnight. The d <
1.006 g/ml lipoproteins (‘‘chylomicrons’’) were isolated by centrifuga-
tion at 100,000 rpm in a Beckman TLA 100.3 rotor for 6 hr at 4C.
The DiI-labeled chylomicrons were harvested and dialyzed against
PBS containing 5.0 mM EDTA.
To evaluate the binding of the DiI-labeled chylomicrons to GPIHBP1,
transfected CHO ldlA7 cells were incubated with 1 mg/ml of DiI-labeled
chylomicrons in PBS containing 1.0 mM CaCl2, 1.0 mM MgCl2, and
0.5% BSA for 2 hr at 4C. The cells were then washed five times in
the same buffer and fixed in 3% paraformaldehyde, and chylomicron
binding was detected by fluorescence microscopy. Cells expressing
GPIHBP1 on the cell surface were detected by immunofluorescence
microscopy as described above.
Binding of Apolipoprotein AV-Phospholipid Disks to Cells
An apo-AV-FLAG expression vector was constructed by replacing the
apo-AV coding sequence in the apo-AV/pET vector (Beckstead et al.,
2003) with sequences encoding apo-AV-FLAG. Recombinant apo-AV
with a carboxy-terminal 8-residue FLAG extension was expressed and
purified as described (Beckstead et al., 2003). To generate apo-
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GPIHBP1 in Lipolysis(DMPC) was dissolved in chloroform:methanol (3:1 v/v), and the sol-
vent was evaporated under a stream of nitrogen. The sample was
then incubated in vacuo for 16 hr to remove residual solvent. DMPC
was resuspended in a solution containing 50 mM sodium citrate and
150 mM NaCl (pH 3.0), followed by the addition of apo-AV-FLAG
(6:1 DMPC:apoA-V w/w). The mixture was sonicated until clear; dia-
lyzed against 50 mM phosphate (pH 7.4), 150 mM NaCl; and filter ster-
ilized (0.22 mM). Protein concentration was determined with the BCA
Protein Assay Kit (Pierce), and the phospholipid content was deter-
mined with an enzyme-based colorimetric assay (Wako). To evaluate
the binding of the apo-AV-DMPC disks to GPIHBP1, pgsA-745 CHO
cells were transiently transfected with the S protein-tagged Gpihbp1
cDNA and incubated with 5 mg/ml of apo-AV-DMPC disks in PBS con-
taining 1.0 mM CaCl2, 1.0 mM MgCl2, and 0.5% BSA for 2 hr at 4
C.
Apoprotein binding was detected with mouse anti-FLAG antibody
(and Cy5-conjugated goat anti-mouse antibody), and the S protein-
tagged GPIHBP1 was assessed as described above.
Supplemental Data
Supplemental Data include seven figures and can be found with this
article online at http://www.cellmetabolism.org/cgi/content/full/5/4/
279/DC1/.
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